Table 1 Patient characteristics.

From: Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors

 

Total (N = 94)

N

%

Age

≤ 70 (median)

48

51.1

> 70 (median)

46

48.9

Sex

Male

76

80.9

Female

18

19.1

ECOG PS

0, 1

70

74.5

2, 3

24

25.5

Regimen

Nivolumab

65

69.1

Pembrolizumab

29

30.9

ICI treatment linea

1st

64

68.1

2nd

21

22.3

3rd or more

9

9.6

BOR

Non-PD

61

64.9

(CR)

(1)

(1.1)

(PR)

(18)

(19.2)

(SD)

(42)

(44.7)

PD

33

35.1

BNML

One

42

44.7

More

52

55.3

BSLD

≤ 28

33

35.1

> 28

61

64.9

SUVmax

≤ 12.93

23

24.5

> 12.93

25

26.6

unknown

46

48.9

  1. ECOG Eastern Cooperative Oncology Group, PS performance status, ICI immune checkpoint inhibitor, BOR best overall response, PD progressive disease, BNML baseline number of metastatic lesions, BSLD baseline sum of target lesions' longest diameters, SUV standardized uptake value.
  2. aICI treatment line was counted as the number of systemic chemotherapy for recurrent or metastatic head and neck cancer.
Back to article page